腺癌
克里唑蒂尼
癌症研究
肺
医学
肺癌
内科学
肿瘤科
癌症
恶性胸腔积液
作者
Pandeng Wang,Zhuo Jiang,Jianji Guo,Bo Liu,Zhen Liu,Dongdong Wang,Honglin Li
标识
DOI:10.3389/fphar.2024.1433894
摘要
Lung cancer is a prevalent malignancy, with the rearrangement of the anaplastic lymphoma kinase (ALK) gene being responsible for a minority of cases of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion proteins demonstrate sensitivity to ALK tyrosine kinase inhibitors (TKIs). In this report, we describe the case of a female patient with metastatic lung adenocarcinoma, identified through NGS to carry a rare inverted SQSTM1-ALK (S5, A20) fusion. The patient received ensartinib as first-line therapy, resulting in a partial response (PR). At the time of publication, the patient’s condition remained favorable. We have, for the first time, identified the presence of SQSTM1-ALK fusion in pericardial effusion, with the favorable response to ensartinib validating the oncogenic potential of SQSTM1-ALK fusion. The substantial advancements and extensive utilization of NGS have facilitated the identification of rare fusion variants.
科研通智能强力驱动
Strongly Powered by AbleSci AI